Baidu
map

J Hematol Oncol:近30年全球29种癌症的发生率及死亡率

2021-11-28 Nebula MedSci原创

全球癌症负担持续增加……

癌症很快会成为21世纪每个国家的主要死亡原因。本研究旨在分析1990-2019年204个国家或地区29种癌症的发病率和死亡率,以指导全球的癌症预防和控制策略。

研究人员从2019年的全球疾病负担研究中收集了29种癌症团体的详细信息。按性别、年龄、地区和国家分层计算29种癌症的年龄标准化发病率 (ASIR) 和年龄标准化死亡率 (ASDR)。此外,对常见癌症类型进行单独分析。

2019年全球癌症的总年龄标准化死亡率

2019年,全球约有1000多万人死于癌症,大约是1990年的两倍。气管、支气管和肺癌 (TBL) 的总体死亡率最高,胰腺癌的年龄标准化死亡率升高了24%,是病死率最高的癌症 (CFR)。全球癌症的年龄标准化发病率呈上升趋势,睾丸癌、甲状腺癌、恶性皮肤黑素瘤呈显著上升趋势。男性癌症的年龄标准化发病率和年龄标准化死亡率约为女性的1.5倍。

2019年全球癌症的致死率

50岁以上的人群患癌症的风险最高,该年龄组的发病率和死亡率占所有年龄组癌症发病率和死亡率的85%以上。由于人口密度高,亚洲是癌症负担最重的地区,该地区食管癌死亡人数占全世界食管癌死亡人数的53%。

此外,根据世界银行人类发展指数 (HDI),大多数癌症的死亡率和发病率随着社会人口指数的增加而升高。最后,全球不同国家的癌症特征各不相同。

全球癌症相关死亡病例数的变化趋势

总之,全球癌症负担持续增加,不同区域、年龄、国家、性别和癌症类型之间的死亡率和发病率存在很大差异。有效的、因地制宜的癌症预防和控制措施对减少未来全球癌症负担至关重要。

原始出处:

Lin Longfei,Li Zhiyong,Yan Lei et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019.[J] .J Hematol Oncol, 2021, 14: 197.https://doi.org/10.1186/s13045-021-01213-z

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866380, encodeId=277b186638090, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Dec 01 12:47:27 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826754, encodeId=ab561826e5479, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 31 08:47:27 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 13:47:27 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075167, encodeId=a43b10e516797, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Mon Nov 29 20:06:37 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074954, encodeId=917810e495450, content=或病人有胸痛时,立即停药及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Nov 29 07:05:34 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-12-01 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866380, encodeId=277b186638090, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Dec 01 12:47:27 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826754, encodeId=ab561826e5479, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 31 08:47:27 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 13:47:27 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075167, encodeId=a43b10e516797, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Mon Nov 29 20:06:37 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074954, encodeId=917810e495450, content=或病人有胸痛时,立即停药及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Nov 29 07:05:34 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866380, encodeId=277b186638090, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Dec 01 12:47:27 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826754, encodeId=ab561826e5479, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 31 08:47:27 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 13:47:27 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075167, encodeId=a43b10e516797, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Mon Nov 29 20:06:37 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074954, encodeId=917810e495450, content=或病人有胸痛时,立即停药及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Nov 29 07:05:34 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-30 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866380, encodeId=277b186638090, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Dec 01 12:47:27 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826754, encodeId=ab561826e5479, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 31 08:47:27 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 13:47:27 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075167, encodeId=a43b10e516797, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Mon Nov 29 20:06:37 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074954, encodeId=917810e495450, content=或病人有胸痛时,立即停药及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Nov 29 07:05:34 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-29 清漩

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1866380, encodeId=277b186638090, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Dec 01 12:47:27 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826754, encodeId=ab561826e5479, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 31 08:47:27 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 13:47:27 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075167, encodeId=a43b10e516797, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Mon Nov 29 20:06:37 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074954, encodeId=917810e495450, content=或病人有胸痛时,立即停药及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Nov 29 07:05:34 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-29 查查佳佳

    或病人有胸痛时,立即停药及时

    0

相关资讯

Sci Adv:这种廉价的口服药物,让癌症脑转移放疗效果倍增!

晚期肿瘤经常发生脑转移(BM),一旦发生脑转移,患者的生活质量将直线降低。目前可以通过放射治疗缓解脑转移进展。添加辐射增敏剂可能进一步改善肿瘤的控制。然而,血脑屏障(BBB)是一个重大的药理学挑战。

心电图or颅脑MRA?更能找出预后不良的癌症合并卒中患者?

PLOS ONE:颅内动脉粥样硬化和心房颤动对活动性癌症患者缺血性中风的预后的影响

阻塞性睡眠呼吸暂停严重程度和癌症相关死亡率的相关性研究

OSA 的存在可能会增加癌症发展和较差癌症预后的风险。

Nature:促进癌细胞转移!这种食物我们每天都在吃

棕榈酸(PA)是人体内最常见的饱和脂肪酸,占人体内总脂肪酸的 20-30%,平均而言,一个 70 公斤重的人由 3.5 公斤棕榈酸组成。它可由饮食提供,也可体内合成。

对一大串癌症及治疗相关症状束手无策?请“老祖宗”出手帮忙!

Journal of Cancer:针灸与电针在治疗癌症相关症状及副作用的应用。

Nature:新型CAR-T疗法,有望靶向治疗各种类型癌症

以肽为中心的CAR可能极大地扩展免疫治疗靶点库,为通过免疫疗法治疗更广泛的癌症,以及将每种疗法应用于更大比例的人群打开了大门。

Baidu
map
Baidu
map
Baidu
map